Published in Hepat Mon on September 01, 2010
New globally faces of hepatitis B and C in the world. Gastroenterol Hepatol Bed Bench (2011) 1.12
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med (1989) 4.69
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med (1993) 3.53
The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis. Hepat Mon (2010) 1.57
P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma. Cancer (2006) 1.11
Chemoprevention of hepatocellular carcinoma in hepatitis C virus-related cirrhosis: first, eliminate the virus. J Hepatol (2001) 0.89
Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer (2011) 1.19
P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma. Cancer (2006) 1.11
MicroRNA-21 regulates the invasion and metastasis in cholangiocarcinoma and may be a potential biomarker for cancer prognosis. Asian Pac J Cancer Prev (2013) 1.06
High-level expression of periostin is closely related to metastatic potential and poor prognosis of hepatocellular carcinoma. Med Oncol (2012) 1.06
Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials. Int J Cancer (2011) 0.99
Extracellular matrix protein 1, a novel prognostic factor, is associated with metastatic potential of hepatocellular carcinoma. Med Oncol (2010) 0.95
Ligation of TLR2 by versican: a link between inflammation and metastasis. Arch Med Res (2009) 0.95
Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol Lett (2004) 0.92
Activation of STAT3 signal pathway correlates with twist and E-cadherin expression in hepatocellular carcinoma and their clinical significance. J Surg Res (2010) 0.90
Docosahexaenoic acid (DHA) induces apoptosis in human hepatocellular carcinoma cells. Int J Clin Exp Pathol (2013) 0.90
Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma. Dig Dis Sci (2008) 0.89
Estrogen suppresses metastasis in rat hepatocellular carcinoma through decreasing interleukin-6 and hepatocyte growth factor expression. Inflammation (2012) 0.89
Overexpression of Mortalin in hepatocellular carcinoma and its relationship with angiogenesis and epithelial to mesenchymal transition. Int J Oncol (2013) 0.89
Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma. Med Oncol (2014) 0.88
Expression of Smad7 in cholangiocarcinoma: prognostic significance and implications for tumor metastasis. Asian Pac J Cancer Prev (2012) 0.88
Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Cancer (2009) 0.87
Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma. Med Oncol (2013) 0.85
Loss of heterozygosity at D8S298 is a predictor for long-term survival of patients with tumor-node-metastasis stage I of hepatocellular carcinoma. Clin Cancer Res (2007) 0.83
The expression of chitinase 3-like 1: a novel prognostic predictor for hepatocellular carcinoma. J Cancer Res Clin Oncol (2013) 0.83
Overexpression of HOXA13 as a potential marker for diagnosis and poor prognosis of hepatocellular carcinoma. Tohoku J Exp Med (2014) 0.82
Overexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis. Can J Gastroenterol (2010) 0.82
Periostin: a putative mediator involved in tumour resistance to anti-angiogenic therapy? Cell Biol Int (2011) 0.81
STAT3 activation mediates epithelial-to-mesenchymal transition in human hepatocellular carcinoma cells. Hepatogastroenterology (2014) 0.80
Aberrant estrogen receptor alpha expression correlates with hepatocellular carcinoma metastasis and its mechanisms. Hepatogastroenterology (2014) 0.79
Expression of Kindlin-1 in human hepatocellular carcinoma and its prognostic significance. Tumour Biol (2015) 0.79
Octreotide therapy for hepatocellular carcinoma: a systematic review of the evidence from randomized controlled trials. Hepatogastroenterology (2010) 0.78
Clinical characteristics and mechanism of liver damage in patients with severe acute respiratory syndrome. Hepatobiliary Pancreat Dis Int (2005) 0.77
Efficacy and feasibility of radiofrequency ablation for hepatocellular carcinoma patients. Hepatogastroenterology (2013) 0.77
Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma. BMC Cancer (2012) 0.77
Radiofrequency ablation is a valuable therapeutic option in the treatment of liver metastases from gastrointestinal stromal tumors. Cardiovasc Intervent Radiol (2013) 0.77
Protective effects of physiological doses of estrogen during hepatocarcinogenesis induced by diethylnitrosamine and N-nitrosomorpholine. Hepatogastroenterology (2012) 0.76
[Prevention of hepatic tumor growth and metastasis in rats with rapamycin]. Zhonghua Gan Zang Bing Za Zhi (2009) 0.75
[Case-controlled study of entecavir treatment for chronic severe hepatitis B]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi (2009) 0.75
Can hepatocellular carcinoma be treated by Yondelis through targeting both tumor cells and tumor-associated macrophages? Hepatogastroenterology (2010) 0.75